US Stock MarketDetailed Quotes

IMMP Immutep

Watchlist
  • 1.720
  • -0.030-1.71%
Trading Mar 11 10:37 ET
250.36MMarket Cap-8.27P/E (TTM)
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    我要向钱看
    我要向钱看
    Feb 4 19:04
    UPDATES
    $Immutep (IMMP.US)$ Immutep Ltd has released a corporate presentation to update stakeholders on its business activities. The presentation emphasizes the company’s ongoing efforts to harness the immune system for therapeutic purposes, reflecting its dedication to maintaining a strong position in the biotechnology sector. This announcement may impact the company’s market perception and investor confidence, underlining its commitment to innovation and growth in its field.
    我要向钱看
    我要向钱看
    Feb 3 05:57
    UPDATES
    $Immutep (IMMP.US)$ Immutep Limited announced significant advancements in its clinical trials and research efforts, marking a transition to a Phase III biotech company. The company received its first regulatory approval for the pivotal TACTI-004 Phase III trial for non-small cell lung cancer in December 2024, and reported promising results from various other trials, including INSIGHT-003 and EFTISARC-NEO, demonstrating improved survival rates and tumour responses. Additionally, Immutep’s c...
    Jaguar8
    Jaguar8
    Jan 22 07:02
    NEWS
    $Immutep (IMMP.US)$
    Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
    Wednesday, 22nd January at 8:00 am
    Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patients
    Data updates from EFTISARC-NEO expected in 2025
    SYDNEY, AUSTRALIA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology co...
    我要向钱看
    我要向钱看
    Jan 5 17:47
    UPDATES
    $Immutep (IMMP.US)$ Immutep (ASX:IMM) said the phase 1 INSIGHT-003 trial reached an enrollment target of about 50 patients across Germany, according to a Monday Australian bourse filing.
    INSIGHT-003 is an investigator-initiated study led by the Frankfurt Institute of Clinical Cancer Research IKF evaluating a triple combination therapy in first-line non-small cell lung cancer patients.
    It is testing eftilagimod alpha in combination with antiPD-1 therapy, pembrolizumab, and doublet chemoth...
    我要向钱看
    我要向钱看
    Dec 17, 2024 07:40
    UPDATES
    $Immutep (IMMP.US)$ Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential
Read more

Trending Stocks

Market Hot Picks Market Hot Picks
No. Symbol Price
Tesla
TSLA
224.300
NVIDIA
NVDA
106.770
Palantir
PLTR
76.980
4
Apple
AAPL
222.850
5
Advanced Micro Devices
AMD
96.070
Log In for the Full List
Unlock Now